Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Antarex MTX Auto-Injector Reaches Market | Contract Pharma

What are you searching for?

Sign in
Trials & Filings

Antarex MTX Auto-Injector Reaches Market

Otrexup approved in October 2013 for RA, pJIA

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

Antares Pharma has made available Otrexup, the first FDA-approved subcutaneous (SC) methotrexate (MTX) product for once weekly self-administration with an easy-to-use, single dose, disposable auto injector. Otrexup was approved by the FDA in October 2013 and is available at distribution centers throughout the U.S.

Otrexup is indicated for adults with severe active rheumatoid arthritis (RA) who have had an insufficient therapeutic response to or are intolerant of an adequate trial of first line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs), and children with active polyarticular juvenile idiopathic arthritis (pJIA). Otrexup is also indicated for use in adults who need symptomatic control of severe recalcitrant, disabling psoriasis that is not adequately responsive to other forms of therapy.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics